Voglibose

• CAT Number: A000907
• CAS Number: 83480-29-9
• Molecular Formula: C10H21NO7
• Molecular Weight: 267.3
• Purity: ≥95%
• Synonyms: 83480-29-9; Glustat; Basen; AO-128; Vocarb
• Storage: -20°C
• InChI: 1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1
• InChIKey: FZNCGRZWXLXZSZ-CIQUZCHMSA-N
• SMILES: C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO

Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose was first launched in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus. Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal. There are three drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest. Voglibose has fewer side effects than both acarbose and miglitol. But acarbose has an edge over voglibose in terms of efficacy (FPG, PPHG, HBA1c).

Reference

1: Koyama H, Ohguchi H, Yagi T, Imaeda K. Nocturnal reactive hypoglycaemia well
treated subjectively and objectively with voglibose. BMJ Case Rep. 2017 Oct
4;2017. pii: bcr-2017-220295. doi: 10.1136/bcr-2017-220295. PubMed PMID:
28978579.

2: Satoh H, Ohira T, Moriya C, Inoue I, Kuribayashi S, Seino H, Hirai H, Hiyoshi
T, Watada H; L-CGM Study Group. Effects of linagliptin vs. voglibose on daily
glucose excursions during continuous glucose monitoring of Japanese type 2
diabetes patients (L-CGM): A randomized, open-label, two-arm, parallel
comparative trial. Diabetes Metab. 2017 Dec;43(6):550-553. doi:
10.1016/j.diabet.2017.07.010. Epub 2017 Sep 22. PubMed PMID: 28947255.

3: Kanoshima K, Matsuura M, Kaai M, Inoh Y, Ohkuma K, Iida H, Nonaka T, Fujita K,
Ida T, Kusakabe A, Nakajima A, Inamori M. The α-glucosidase inhibitor voglibose
stimulates delayed gastric emptying in healthy subjects: a crossover study with a
(13)C breath test. J Clin Biochem Nutr. 2017 May;60(3):216-218. doi:
10.3164/jcbn.16-100. Epub 2017 Apr 20. PubMed PMID: 28584404; PubMed Central
PMCID: PMC5453016.

4: Arao T, Okada Y, Torimoto K, Sugai K, Otsuka T, Kurozumi A, Tanaka Y.
Comparison Between Effectiveness of 100 mg/day Sitagliptin and a Switch to
Mitiglinide Calcium Hydrate/Voglibose from 50 mg/day Sitagliptin in Patients with
Type 2 Diabetes. J UOEH. 2017;39(1):1-9. doi: 10.7888/juoeh.39.1. PubMed PMID:
28331117.

5: Ihana-Sugiyama N, Yamamoto-Honda R, Sugiyama T, Tsujimoto T, Kakei M, Noda M.
Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a
Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4
Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus. Med
Sci Monit Basic Res. 2017 Feb 28;23:36-44. PubMed PMID: 28242866; PubMed Central
PMCID: PMC5345383.

6: Dash RP, Babu RJ, Srinivas NR. Reappraisal and perspectives of clinical
drug-drug interaction potential of α-glucosidase inhibitors such as acarbose,
voglibose and miglitol in the treatment of type 2 diabetes mellitus. Xenobiotica.
2018 Jan;48(1):89-108. doi: 10.1080/00498254.2016.1275063. Epub 2017 Jan 19.
PubMed PMID: 28010166.

7: Fujitani Y, Fujimoto S, Takahashi K, Satoh H, Hirose T, Hiyoshi T, Ai M, Okada
Y, Gosho M, Mita T, Watada H. Effects of linagliptin monotherapy compared with
voglibose on postprandial blood glucose responses in Japanese patients with type
2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP).
Diabetes Res Clin Pract. 2016 Nov;121:146-156. doi:
10.1016/j.diabres.2016.09.014. Epub 2016 Sep 22. PubMed PMID: 27710821.

8: Shi CH, Wang L, Bai R, Wang YB, Liu D, Zhang XY, Wang H, Yang Y, Du JL.
[Comparison of therapeutic effects between sitagliptin and voglibose both
combined with sensor-augmented insulin pump in newly diagnosed type 2 diabetes].
Zhonghua Yi Xue Za Zhi. 2016 Aug 23;96(32):2554-8. doi:
10.3760/cma.j.issn.0376-2491.2016.32.008. Chinese. PubMed PMID: 27596550.

9: Mori K, Emoto M, Shoji T, Inaba M. Linagliptin monotherapy compared with
voglibose monotherapy in patients with type 2 diabetes undergoing hemodialysis: a
12-week randomized trial. BMJ Open Diabetes Res Care. 2016 Jul 19;4(1):e000265.
doi: 10.1136/bmjdrc-2016-000265. eCollection 2016. PubMed PMID: 27547421; PubMed
Central PMCID: PMC4964246.

10: Tomita T, Goto H, Sumiya K, Yoshida T, Tanaka K, Kohda Y. Effects of Food
Thickeners on the Inhibitory Effect of Voglibose Oral-disintegrating Tablets on
Post-prandial Elevation of Blood Sugar Levels. Yakugaku Zasshi.
2016;136(8):1171-6. doi: 10.1248/yakushi.15-00272. PubMed PMID: 27477734.